APO Research
Talk to an analyst

APO RESEARCH · REPORT

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine

Compare research editions
View pricing & licenses

Selected research

Industry Research

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Research Report 2026

20 December 2025122 pages

Choose your research edition.

Industry ResearchDiphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine include Astellas Pharma US, Emergent BioSolutions Inc, Merck Sharp & Dohme Corp, Protein Sciences Corporation, Sanofi Pasteur, Seqirus, AstraZeneca, GlaxoSmithKline and Pfizer Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market by Company

Astellas Pharma US

Emergent BioSolutions Inc

Merck Sharp & Dohme Corp

Protein Sciences Corporation

Sanofi Pasteur

Seqirus

AstraZeneca

GlaxoSmithKline

Pfizer Inc

Lanzhou Institute of Biological Products Co., Ltd

Novartis AG

Johnson & Johnson

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Segment by Type

Immune DTaP Vaccine

Therapy DTaP Vaccine

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Segment by Application

Adult

Pediatric

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units) of Manufacturers (2021-2026) Table 7. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Manufacturers (2021-2026) Table 8. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue of Manufacturers (2021-2026) Table 9. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, Product Type & Application Table 14. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Astellas Pharma US Company Information Table 19. Astellas Pharma US Business Overview Table 20. Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 22. Astellas Pharma US Recent Developments Table 23. Emergent BioSolutions Inc Company Information Table 24. Emergent BioSolutions Inc Business Overview Table 25. Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 27. Emergent BioSolutions Inc Recent Developments Table 28. Merck Sharp & Dohme Corp Company Information Table 29. Merck Sharp & Dohme Corp Business Overview Table 30. Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 32. Merck Sharp & Dohme Corp Recent Developments Table 33. Protein Sciences Corporation Company Information Table 34. Protein Sciences Corporation Business Overview Table 35. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 37. Protein Sciences Corporation Recent Developments Table 38. Sanofi Pasteur Company Information Table 39. Sanofi Pasteur Business Overview Table 40. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 42. Sanofi Pasteur Recent Developments Table 43. Seqirus Company Information Table 44. Seqirus Business Overview Table 45. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 47. Seqirus Recent Developments Table 48. AstraZeneca Company Information Table 49. AstraZeneca Business Overview Table 50. AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 52. AstraZeneca Recent Developments Table 53. GlaxoSmithKline Company Information Table 54. GlaxoSmithKline Business Overview Table 55. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 57. GlaxoSmithKline Recent Developments Table 58. Pfizer Inc Company Information Table 59. Pfizer Inc Business Overview Table 60. Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 62. Pfizer Inc Recent Developments Table 63. Lanzhou Institute of Biological Products Co., Ltd Company Information Table 64. Lanzhou Institute of Biological Products Co., Ltd Business Overview Table 65. Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 67. Lanzhou Institute of Biological Products Co., Ltd Recent Developments Table 68. Novartis AG Company Information Table 69. Novartis AG Business Overview Table 70. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 72. Novartis AG Recent Developments Table 73. Johnson & Johnson Company Information Table 74. Johnson & Johnson Business Overview Table 75. Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 77. Johnson & Johnson Recent Developments Table 78. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 79. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2021-2026) & (W Units) Table 80. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2021-2026) Table 81. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2027-2032) & (W Units) Table 82. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2027-2032) Table 83. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 84. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region (2021-2026) Table 85. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 86. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region (2027-2032) Table 87. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021-2026) & (W Units) Table 89. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2027-2032) & (W Units) Table 90. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 91. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 92. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021-2026) & (W Units) Table 94. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2027-2032) & (W Units) Table 95. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 96. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 97. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021-2026) & (W Units) Table 99. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2027-2032) & (W Units) Table 100. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 101. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 102. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021-2026) & (W Units) Table 104. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2027-2032) & (W Units) Table 105. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 106. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 107. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021-2026) & (W Units) Table 109. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2027-2032) & (W Units) Table 110. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 111. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 112. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021-2026) & (W Units) Table 113. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2027-2032) & (W Units) Table 114. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2021-2026) Table 115. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2027-2032) Table 116. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 117. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 118. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2021-2026) Table 119. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2027-2032) Table 120. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2021-2026) & (US$/Unit) Table 121. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2027-2032) & (US$/Unit) Table 122. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021-2026) & (W Units) Table 123. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2027-2032) & (W Units) Table 124. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2021-2026) Table 125. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2027-2032) Table 126. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 127. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 128. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2021-2026) Table 129. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2027-2032) Table 130. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2021-2026) & (US$/Unit) Table 131. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2027-2032) & (US$/Unit) Table 132. Key Raw Materials Table 133. Raw Materials Key Suppliers Table 134. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Distributors List Table 135. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Customers List Table 136. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Trends Table 137. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Drivers Table 138. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Restraints Table 139. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Image Figure 5. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size (2021-2032) & (US$ Million) Figure 7. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (2021-2032) & (W Units) Figure 8. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Average Price (US$/Unit) & (2021-2032) Figure 9. Immune DTaP Vaccine Product Image Figure 10. Therapy DTaP Vaccine Product Image Figure 11. Adult Product Image Figure 12. Pediatric Product Image Figure 13. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Manufacturers in 2025 Figure 14. Global Manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, Manufacturing Sites & Headquarters Figure 15. Global Top 5 and 10 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Players Market Share by Revenue in 2025 Figure 16. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 18. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region in 2025 Figure 19. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region in 2025 Figure 20. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country in 2025 Figure 21. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country (2021-2032) Figure 22. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Country (2021-2032) Figure 23. United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 24. Canada Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country in 2025 Figure 26. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country (2021-2032) Figure 27. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Country (2021-2032) Figure 28. Germany Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. France Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. U.K. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Italy Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Netherlands Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country in 2025 Figure 34. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country (2021-2032) Figure 35. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Country (2021-2032) Figure 36. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Japan Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. South Korea Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. India Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Australia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. China Taiwan Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Southeast Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Southeast Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country in 2025 Figure 45. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country (2021-2032) Figure 46. South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Country (2021-2032) Figure 47. Mexico Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Brazil Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Argentina Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country in 2025 Figure 51. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country (2021-2032) Figure 52. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Country (2021-2032) Figure 53. Turkey Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Saudi Arabia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. UAE Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2021-2032) Figure 57. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2021-2032) Figure 58. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price (US$/Unit) by Type (2021-2032) Figure 59. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2021-2032) Figure 60. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2021-2032) Figure 61. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price (US$/Unit) by Application (2021-2032) Figure 62. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Value Chain Figure 63. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Mode & Process Figure 64. Direct Comparison with Distribution Share Figure 65. Distributors Profiles Figure 66. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Opportunities and Challenges

Scope & coverage.

Types
  • Immune DTaP Vaccine
  • Therapy DTaP Vaccine
Applications
  • Adult
  • Pediatric
Companies covered
  • Astellas Pharma US
  • Emergent BioSolutions Inc
  • Merck Sharp & Dohme Corp
  • Protein Sciences Corporation
  • Sanofi Pasteur
  • Seqirus
  • AstraZeneca
  • GlaxoSmithKline
  • Pfizer Inc
  • Lanzhou Institute of Biological Products Co., Ltd
  • Novartis AG
  • Johnson & Johnson

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size (2021-2032)
  4. 2.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (2021-2032)
  5. 2.2.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Average Price (2021-2032)
  6. 2.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Immune DTaP Vaccine
  9. 2.3.3 Therapy DTaP Vaccine
  10. 2.4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Adult
  13. 2.4.3 Pediatric
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units) of Manufacturers (2021-2026)
  3. 3.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, Product Type & Application
  8. 3.8 Global Manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, Established Date
  9. 3.9 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Astellas Pharma US
  2. 4.1.1 Astellas Pharma US Company Information
  3. 4.1.2 Astellas Pharma US Business Overview
  4. 4.1.3 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  6. 4.1.5 Astellas Pharma US Recent Developments
  7. 4.2 Emergent BioSolutions Inc
  8. 4.2.1 Emergent BioSolutions Inc Company Information
  9. 4.2.2 Emergent BioSolutions Inc Business Overview
  10. 4.2.3 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  12. 4.2.5 Emergent BioSolutions Inc Recent Developments
  13. 4.3 Merck Sharp & Dohme Corp
  14. 4.3.1 Merck Sharp & Dohme Corp Company Information
  15. 4.3.2 Merck Sharp & Dohme Corp Business Overview
  16. 4.3.3 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  18. 4.3.5 Merck Sharp & Dohme Corp Recent Developments
  19. 4.4 Protein Sciences Corporation
  20. 4.4.1 Protein Sciences Corporation Company Information
  21. 4.4.2 Protein Sciences Corporation Business Overview
  22. 4.4.3 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  24. 4.4.5 Protein Sciences Corporation Recent Developments
  25. 4.5 Sanofi Pasteur
  26. 4.5.1 Sanofi Pasteur Company Information
  27. 4.5.2 Sanofi Pasteur Business Overview
  28. 4.5.3 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  30. 4.5.5 Sanofi Pasteur Recent Developments
  31. 4.6 Seqirus
  32. 4.6.1 Seqirus Company Information
  33. 4.6.2 Seqirus Business Overview
  34. 4.6.3 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  36. 4.6.5 Seqirus Recent Developments
  37. 4.7 AstraZeneca
  38. 4.7.1 AstraZeneca Company Information
  39. 4.7.2 AstraZeneca Business Overview
  40. 4.7.3 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  42. 4.7.5 AstraZeneca Recent Developments
  43. 4.8 GlaxoSmithKline
  44. 4.8.1 GlaxoSmithKline Company Information
  45. 4.8.2 GlaxoSmithKline Business Overview
  46. 4.8.3 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  48. 4.8.5 GlaxoSmithKline Recent Developments
  49. 4.9 Pfizer Inc
  50. 4.9.1 Pfizer Inc Company Information
  51. 4.9.2 Pfizer Inc Business Overview
  52. 4.9.3 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  54. 4.9.5 Pfizer Inc Recent Developments
  55. 4.10 Lanzhou Institute of Biological Products Co., Ltd
  56. 4.10.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
  57. 4.10.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
  58. 4.10.3 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  60. 4.10.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
  61. 4.11 Novartis AG
  62. 4.11.1 Novartis AG Company Information
  63. 4.11.2 Novartis AG Business Overview
  64. 4.11.3 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  66. 4.11.5 Novartis AG Recent Developments
  67. 4.12 Johnson & Johnson
  68. 4.12.1 Johnson & Johnson Company Information
  69. 4.12.2 Johnson & Johnson Business Overview
  70. 4.12.3 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  72. 4.12.5 Johnson & Johnson Recent Developments
5 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Scenario by Region
  1. 5.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region: 2021-2032
  3. 5.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region: 2021-2026
  4. 5.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region: 2027-2032
  5. 5.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region: 2021-2032
  6. 5.3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region: 2021-2026
  7. 5.3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region: 2027-2032
  8. 5.4 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Facts & Figures by Country
  9. 5.4.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021-2032)
  11. 5.4.3 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Facts & Figures by Country
  15. 5.5.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021-2032)
  17. 5.5.3 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Facts & Figures by Country
  35. 5.7.1 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021-2032)
  37. 5.7.3 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021-2032)
  2. 6.1.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021-2032) & (W Units)
  3. 6.1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2021-2032)
  4. 6.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2021-2032)
  5. 6.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021-2032)
  2. 7.1.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021-2032) & (W Units)
  3. 7.1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2021-2032)
  4. 7.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2021-2032)
  5. 7.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Value Chain Analysis
  2. 8.1.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Mode & Process
  5. 8.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Distributors
  8. 8.2.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Customers
9 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Analyzing Market Dynamics
  1. 9.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Trends
  2. 9.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Drivers
  3. 9.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Opportunities and Challenges
  4. 9.4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst